Xilio Therapeutics
33 hedge funds and large institutions have $12.6M invested in Xilio Therapeutics in 2024 Q3 according to their latest regulatory filings, with 5 funds opening new positions, 9 increasing their positions, 4 reducing their positions, and 3 closing their positions.
2,506% more capital inflows, than outflows
Capital inflows: $1.32M | Capital outflows: $50.5K
125% more repeat investments, than reductions
Existing positions increased: 9 | Existing positions reduced: 4
67% more first-time investments, than exits
New positions opened: 5 | Existing positions closed: 3
6% more funds holding
Funds holding: 31 → 33 (+2)
0% more funds holding in top 10
Funds holding in top 10: 2 → 2 (0)
3.01% less ownership
Funds ownership: 39.31% → 36.3% (-3%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Bain Capital Life Sciences Investors
Boston,
Massachusetts
|
+$685K |
| 2 |
Morgan Stanley
New York
|
+$359K |
| 3 |
Geode Capital Management
Boston,
Massachusetts
|
+$136K |
| 4 |
Engineers Gate Manager
New York
|
+$28.7K |
| 5 |
Two Sigma Securities
New York
|
+$27.3K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Renaissance Technologies
New York
|
-$25.2K |
| 2 |
Charles Schwab
San Francisco,
California
|
-$11.3K |
| 3 |
XTX Topco
George Town,
Cayman Islands
|
-$8.27K |
| 4 |
Avantax Planning Partners
Dubuque,
Iowa
|
-$3.96K |
| 5 |
ADAR1 Capital Management
Austin,
Texas
|
-$1.42K |
XLO Hedge Fund Activity: Q3 2024 in Review
33 of the 6,987 institutional investors tracked by Wall St. Rank reported a position in Xilio Therapeutics (XLO) for Q3 2024, worth a combined $12.6M — down 8.5% from $13.7M a quarter earlier.
Buyers outnumbered sellers: 5 funds opened new XLO positions and 3 closed out — a net gain of 2 holders — while 9 added to existing stakes and 4 trimmed.
The largest buyer was Bain Capital Life Sciences Investors, adding an estimated $685K. The largest seller was Renaissance Technologies, cutting an estimated $25.2K.
- 33 institutional investors held Xilio Therapeutics (XLO) as of Q3 2024, up from 31 in Q2 2024.
- Funds reported $12.6M of Xilio Therapeutics stock for Q3 2024, down 8.5% quarter-over-quarter.
- 5 funds opened new Xilio Therapeutics positions in Q3 2024 and 3 closed out, a net change of +2 holders.
- The largest Xilio Therapeutics buyer in Q3 2024 was Bain Capital Life Sciences Investors, an estimated $685K added.
- The largest Xilio Therapeutics seller in Q3 2024 was Renaissance Technologies, an estimated $25.2K sold.
Based on aggregated 13F filings for Q3 2024.